Inhibrxの簿価
Inhibrxの簿価 は何ですか。
Inhibrx, Inc.の簿価 は0.51です。
簿価 の定義は何ですか。
1株当たりの帳簿価額は、会社の資産から会社の負債を差し引いた数を発行済株式数で割ったものです。
The book value of a company is the value of its assets according to its balance sheet account balance. For assets, the value is based on the original cost of the asset less any depreciation, amortization or impairment costs made against the asset. Traditionally, a company's book value is its total assets minus intangible assets and liabilities. However, in practice, depending on the source of the calculation, book value may variably include goodwill, intangible assets, or both. The value inherent in its workforce, part of the intellectual capital of a company, is always ignored. The book value of a company may be also referred as with the term net asset value.
The book value per share is the the balance sheet equity value divided by the number of shares outstanding at the date of the balance sheet. Book value per share can be used to generate a measure of comprehensive earnings, when the opening and closing values are reconciled. The sale of shares/units by a business increases the total book value. Book value per share will increase if the additional shares are issued at a price higher than the pre-existing book value per share. The purchase of its own shares by a business will decrease total book value. Book value per share will decrease if more is paid for them than was received when originally issued. Dividends paid out will decrease book value per share value.
NASDAQのセクタHealth Careにおける簿価 の企業と比べるInhibrx
Inhibrxは何をしますか。
Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcinoma; INBRX-105, a tetravalent conditional agonist of programmed death-ligand 1 and a conditional agonist of 4-1BB that is in Phase 1 clinical trials to treat patients with locally advanced or metastatic solid tumors; and INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also provides INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company was founded in 2010 and is headquartered in La Jolla, California.
Inhibrxと類似の簿価
- Chong Hing Bankの簿価 は0.51です。
- Perfectech Internationalの簿価 は0.51です。
- Hancock Jaffe Laboratories Incの簿価 は0.51です。
- Roxgoldの簿価 は0.51です。
- Witbe SAの簿価 は0.51です。
- Planet 13の簿価 は0.51です。
- Inhibrxの簿価 は0.51です。
- Perseus Miningの簿価 は0.51です。
- Fission Uraniumの簿価 は0.51です。
- Coronado Global Resourcesの簿価 は0.51です。
- Stereotaxisの簿価 は0.51です。
- Planet Green Corpの簿価 は0.51です。
- Qianhai Healthの簿価 は0.51です。